Daiichi Sankyo launched its Singapore entity on February 22, 2024

Bringing New Hope for Patients in Singapore

May 07, 2024
Patient Centricity
Share
  • Linkedin (Open new window)
  • clipURL

On February 22, 2024, Daiichi Sankyo launched its Singapore entity, which will be dedicated to bridging unmet needs in oncology, with the hope of extending and improving the lives of cancer patients in Singapore.

Leveraging the country’s strength in being a well-established, scientific innovation hub in the Asia region, the local Daiichi Sankyo Singapore team will take bold steps to drive cutting-edge developments in the field of antibody-drug conjugate (ADC) technology.

Daiichi Sankyo President & COO, Hiroyuki Okuzawa, delivers
the inauguration speech at the launch event

To celebrate the beginning of Daiichi Sankyo’s footprint in the country, our Representative Director, President & COO, Hiroyuki Okuzawa, and Ken Takeshita, our Head of Research & Development, joined the launch event in Singapore together with Koichi Morino, Managing Director of Daiichi Sankyo Singapore and the rest of the Singapore team. Mr. Okuzawa shared his excitement for Daiichi Sankyo Singapore to embark on this new journey in his inauguration speech, saying. “Our permanent footprint in Singapore will not only enable us to foster an already strong science-centric workforce in the country, but also allow us to fully focus on patient-centric innovation to address unmet healthcare needs in Singapore and beyond with a robust pipeline.”

From left: Mr. Ken Takeshita, Head of Research & Development;
Mr. Hiroyuki Okuzawa; His Excellency Hiroshi Ishikawa,
Ambassador of Japan to Singapore; Mr. Tan Kong Hwee, Executive
Vice President of Singapore’s Economic Development Board; and
Mr. Koichi Morino, Managing Director of Daiichi Sankyo Singapore

The event was also graced by guests of honor, Mr. Tan Kong Hwee, Executive Vice President of Singapore’s Economic Development Board, and His Excellency Hiroshi Ishikawa, Ambassador of Japan to Singapore. Alongside our guests of honor, our local Singapore colleagues also hosted guests from across local government institutions, patient advocacy groups, and media outlets. The event marked a significant milestone in our commitment to bringing our passion for innovation to support and transform outcomes for the oncology community in Singapore.

Since the formation of Daiichi Sankyo through the merger of its predecessor companies, each with over 100 years of history, patient-centricity has always been at the heart of the business. This emphasis will be even stronger within the Singapore office as the team expands the Daiichi Sankyo oncology therapeutics pipeline. “Our vision of creating shared value also extends to society, as we strive to engage in a dialogue with various stakeholders to gain a deeper understanding of the social and healthcare-related issues that we must address,” shared Mr. Okuzawa.

A display of skilfully cultivated bonsai plants, each representing
Daiichi Sankyo Singapore’s commitment to patients, partners and
society in Singapore (Courtesy of Bonsai-inc*)

As a reminder of our rich Japanese history, the launch event featured a display of three skillfully cultivated bonsai plants, each representing Daiichi Sankyo Singapore’s commitment to patients, partners, and society in Singapore.

An interactive exhibition hosted by our local Singapore colleagues also highlighted the Daiichi Sankyo story, from our beginnings as Sankyo Co. Ltd. and Daiichi Pharmaceutical to our strengths in research and development today.

Daiichi Sankyo Singapore Managing Director, Koichi Morino, added, “We are committed to our patients, partners, and society in Singapore to bring faster access to novel life-saving cancer treatments and to address unmet medical needs with integrity and accountability.

Managing Director of Daiichi Sankyo Singapore,
Koichi Morino

We strongly stand by these commitments and believe there is even more we can achieve in tandem. The Singapore office is also home to the newly set up Research & Development and Pharmacovigilance Quality Assurance (RDPV QA) function, signifying a strategic leap forward in reinforcing the company’s commitment to patients, customers, and rigorous quality assurance in all that we do. The office will function as the RDPV QA’s Asia Pacific regional hub, and will be a center of excellence, driving the mission of “Patient first, Quality Always,” while ensuring the highest quality standards in Research & Development, Pharmacovigilance, Medical Affairs and key processes and systems across the region.

With their eyes set on the future ahead, the Daiichi Sankyo Singapore team is excited to drive new innovations forward and work hand-in-hand with our partners to make a tangible impact for patients in Singapore.

The Daiichi Sankyo Singapore team

Share
  • Linkedin (Open new window)
  • clipURL

* These real bonsais with wellness and aesthetic flow are from Bonsai-inc, on rental to Daiichi Sankyo for the event.